Rebecca H Haberman, Katrina A MacFarlane, Sydney Catron, Jonathan Samuels, Rebecca B Blank, Michael Toprover, Zakwan Uddin, Jiyuan Hu, Rochelle Castillo, Cinty Gong, Kun Qian, Vincent Piguet, Francisco Tausk, Jensen Yeung, Andrea L Neimann, Wayne Gulliver, Ralf G Thiele, Joseph F Merola, Alexis Ogdie, Proton Rahman, Soumya D Chakravarty, Lihi Eder, C T Ritchlin, Jose U Scher
INTRODUCTION: Psoriatic arthritis (PsA) is a complex, immune-mediated disease associated with skin psoriasis that, if left untreated, can lead to joint destruction. Up to 30% of patients with psoriasis progress to PsA. In most cases, psoriasis precedes synovio-entheseal inflammation by an average of 5-7 years, providing a unique opportunity for early and potentially preventive intervention in a susceptible and identifiable population. Guselkumab is an effective IL-23p19 inhibitor Food and Drug Administration (FDA-approved for treatment of moderate-to-severe psoriasis and PsA...
December 23, 2022: BMJ Open